BioSpace News Archive

Bristol Myers Squibb’s Reblozyl induced nearly twice the red blood cell transfusion independence compared with the current standard treatment epoetin alfa for lower-risk myelodysplastic syndrome.

The New York–based biotech will present data from a Phase I trial of 98 patients showing that fianlimab combined with Libtayo led to an overall response rate of 61% in advanced melanoma.

The Insight Partners published latest research study on “Diabetes Care Devices Market Forecast to 2028 - COVID-19

Eli Lilly’s recently registered Phase IIIb SURMOUNT-5 trial will compare its Mounjaro with Novo Nordisk’s Wegovy in obese or overweight patients with weight-related health conditions.

The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.

Genexine announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy for HNSCC in the ASCO.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology annual meeting to be held in Chicago, IL.

TScan Therapeutics, Inc. announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant.

RELIEF THERAPEUTICS Holding SA announced the Annual General Meeting of shareholders will take place Tues., June 20, 2023 at 9 a.m. CEST at avenue de Sécheron 15 in Geneva, near the Relief Therapeutics offices.

Innate Pharma SA announced that the abstract entitled “A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia” was published on the ASCO 2023 Annual Meeting website.